Sangamo Therapeutics

Headquarters: Richmond, California, USA Ticker: SGMO (NASDAQ) Founded: 1995 Website: [sangamo.com](https://www.sangamo.com)

Overview

Headquarters: Richmond, California, USA Ticker: SGMO (NASDAQ) Founded: 1995 Website: [sangamo.com](https://www.sangamo.com)

Overview

Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on gene therapy, gene editing, and cell therapy for patients with serious genetic diseases, neurological conditions, and other high unmet needs["@sangamo2024"]. The company has developed a proprietary zinc finger protein (ZFP) technology platform that enables precise genome editing and regulation of gene expression["@zinc2020"].

Sangamo's zinc finger platform represents one of the earliest gene editing technologies, predating CRISPR-Cas9 by over a decade. The company has leveraged this expertise to build a diversified pipeline spanning neurology, oncology, and immunology.

Pipeline

Neurology Programs

| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| ST-501 | Parkinson's disease | ZFP-TF targeting tau | Preclinical |
| ST-502 | Parkinson's disease | Alpha-synuclein modulation | Preclinical |
| TX-200 | CAR-Treg | Autoimmune | Phase 1 |

ST-501 (Tau-Targeted ZFP Transcription Factor)

ST-501 is Sangamo's lead neurological program, using zinc finger protein transcription factors (ZFP-TFs) to regulate the expression of the MAPT gene encoding tau protein. This approach aims to:

• Reduce pathological tau expression in the brain
• Potentially slow or halt the progression of tauopathies including Alzheimer's disease
• Deliver via AAV vector targeting neurons

ST-502 (Alpha-Synuclein-Targeted ZFP)

ST-502 targets the SNCA gene encoding alpha-synuclein, the protein that forms Lewy bodies in Parkinson's disease. The ZFP-TF approach allows:

• Precise downregulation of alpha-synuclein expression
• Potential modification of disease progression in PD and related synucleinopathies
• Novel mechanism distinct from antibody approaches

Oncology Programs

| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| KITE-361 | Prostate cancer | CAR-T (PSMA) | Phase 1 |
| GLPG | Various | Multiple candidates | Discovery |

Immunology Programs

| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| TX-200 | Autoimmune | CAR-Treg | Phase 1 |

Technology Platform

Zinc Finger Proteins (ZFPs)

Sangamo's platform is based on zinc finger proteins (ZFPs), which are transcription factors that can be engineered to bind to specific DNA sequences. Key features include:

• Precision Binding: ZFPs can be designed to recognize specific 3-base pair DNA sequences, allowing highly specific targeting
• Multiple Configurations: Can function as activators, repressors, nucleases (ZFN), or base editors
• Durability: Once integrated, ZFP expression can provide long-term gene regulation

ZFP Transcription Factors (ZFP-TFs)

ZFP-TFs are engineered transcription factors that can either activate or repress gene expression without cutting DNA. This approach offers:

• Reversible gene modulation (for promoters/enhancers)
• Lower risk of off-target effects compared to nucleases
• Potential for fine-tuning expression levels

ZFP Nucleases (ZFNs)

For permanent gene editing, Sangamo uses ZFP nucleases that create double-strand breaks at precise genomic locations:

• HDR-mediated gene insertion
• NHEJ-mediated gene disruption
• Clinical validation in multiple programs since 2009

Manufacturing

Sangamo has developed a proprietary manufacturing platform for:

• AAV vector production at clinical scale
• Plasmid and helper plasmid production
• Purification and formulation for clinical use

Research Collaborations

Biogen Collaboration

Sangamo entered a strategic partnership with Biogen in 2020 for neurological disease programs worth up to $2.7 billion[@biogen]. The collaboration focuses on:

• Co-development of ZFP therapeutics for Alzheimer's and Parkinson's disease
• Shared discovery and commercialization rights
• Multiple targets under the partnership

Pfizer Collaboration

• Hemophilia A and B gene therapy programs
• Clinical development ongoing
• Earlier partnership laid groundwork for ZFP technology validation

Sanofi Partnership

• Immune cell engineering for oncology
• CAR-T collaboration utilizing Sangamo's ZFP platform

Clinical Development

Sangamo has advanced multiple programs through clinical trials:

• Phase 1/2 Studies: Completed safety and preliminary efficacy studies in hemophilia
• Regulatory Experience: Established relationships with FDA and EMA
• Long-term Follow-up: Tracking patients in long-term follow-up studies

Financials

| Metric | Value |
|--------|-------|
| Market Cap | ~$200M (2024) |
| Cash Position | ~$150M (Q3 2024) |
| R&D Budget | ~$100M annually |
| Employees | ~500 |

Leadership

• Current CEO: The company has transitioned through multiple leadership changes
• Scientific Advisory Board: Includes pioneers in gene therapy and zinc finger technology

Challenges and Considerations

• Competition: CRISPR and other gene editing technologies have gained significant ground
• Clinical Delays: Some programs have experienced clinical holds or delays
• Funding Constraints: Market capitalization has limited resources for large trials
• Partnership Dependence: Heavy reliance on partner funding for clinical development
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)
• [Gene Therapy](/therapeutics/gene-therapy)
• Zinc Finger Proteins

External Links

• [Sangamo Official Website](https://www.sangamo.com)
• [Sangamo Pipeline](https://www.sangamo.com/pipeline)
• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References